| Name | Title | Contact Details |
|---|
Adgero Biopharmaceuticals Holdings, Inc. is a privately-held biopharmaceutical company focused on building a pipeline by advancing its proprietary late stage photodynamic therapy ("PDT") platform with broad utility for the treatment of serious oncology indications. Its lead product candidate, REM-001 Therapy, has demonstrated promising safety and efficacy in four Phase 2/3 clinical studies in patients with cutaneous metastatic breast cancer ("CMBC") who have failed radiation therapy. Use of Adgero`s existing data or the completion of a Phase 3 trial in individuals with CMBC could lead to approval of REM-001 Therapy.
Royal Danish Consulate is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ankyra is developing cancer therapies based on localized cytokines that prime a systemic adaptive immune response.
Angstrom Scientific is a Ramsey, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Talis is developing a new class of diagnostic platform to enable rapid, high-complexity testing across a wide range of healthcare settings.